SWITCH TO NATALIZUMAB OR FINGOLIMOD IN PATIENTS WITH ACTIVE MULTIPLE SCLEROSIS WHO FAILED FIRST-LINE THERAPIES: AN OBSERVATIONAL, BICENTER, COMPARISON STUDY.